DK1784181T3 - VEGF inhibition - Google Patents

VEGF inhibition

Info

Publication number
DK1784181T3
DK1784181T3 DK05776195.9T DK05776195T DK1784181T3 DK 1784181 T3 DK1784181 T3 DK 1784181T3 DK 05776195 T DK05776195 T DK 05776195T DK 1784181 T3 DK1784181 T3 DK 1784181T3
Authority
DK
Denmark
Prior art keywords
vegf inhibition
vegf
inhibition
Prior art date
Application number
DK05776195.9T
Other languages
Danish (da)
Inventor
David L Morris
Mohammad Hossein Pourgholami
Original Assignee
Newsouth Innovations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004904973A external-priority patent/AU2004904973A0/en
Application filed by Newsouth Innovations Pty Ltd filed Critical Newsouth Innovations Pty Ltd
Application granted granted Critical
Publication of DK1784181T3 publication Critical patent/DK1784181T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK05776195.9T 2004-08-31 2005-08-31 VEGF inhibition DK1784181T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004904973A AU2004904973A0 (en) 2004-08-31 Treatment for Ascites
AU2004904972A AU2004904972A0 (en) 2004-08-31 VEGF Inhibition
PCT/AU2005/001318 WO2006024092A1 (en) 2004-08-31 2005-08-31 Vegf inhibition

Publications (1)

Publication Number Publication Date
DK1784181T3 true DK1784181T3 (en) 2013-09-02

Family

ID=35999633

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05776195.9T DK1784181T3 (en) 2004-08-31 2005-08-31 VEGF inhibition

Country Status (12)

Country Link
US (1) US8912225B2 (en)
EP (1) EP1784181B1 (en)
JP (1) JP5022220B2 (en)
KR (1) KR20070083538A (en)
CN (1) CN101035530B (en)
CA (1) CA2576827A1 (en)
DK (1) DK1784181T3 (en)
ES (1) ES2425750T3 (en)
HK (1) HK1103651A1 (en)
PL (1) PL1784181T3 (en)
PT (1) PT1784181E (en)
WO (1) WO2006024092A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035530B (en) 2004-08-31 2013-07-03 新南部创新有限公司 VEGF inhibition
WO2009043093A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
US20120064008A1 (en) * 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
CN102336740B (en) * 2010-07-27 2013-07-24 中国科学院上海药物研究所 Novel imidazole compound and its application
CN103054858A (en) * 2013-01-21 2013-04-24 杭州雷索药业有限公司 Application of oxibendazole in preparing anti-angiogenesis medicine
KR20210099402A (en) * 2020-02-04 2021-08-12 고려대학교 산학협력단 Pharmaceutical composition for preventing or treating diseases related to abnormal proliferation of endometrial cells or trophoblast cells comprising fenbendazole, oxibendazole or mixture thereof
WO2021184059A1 (en) * 2020-03-14 2021-09-23 Newsouth Innovations Pty Limited Treatment methods
CN113648308A (en) * 2021-09-14 2021-11-16 东莞市人民医院 Application of oxfendazole as anti-ovarian cancer drug

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PL196895B1 (en) 1999-04-28 2008-02-29 Takeda Pharmaceutical Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
KR100816572B1 (en) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Anti-VEGF antibody and a pharmaceutical composition comprising the same
JP2002193947A (en) 2000-12-26 2002-07-10 Taisho Pharmaceut Co Ltd Benzimidazole derivative
JP4688291B2 (en) * 2000-12-28 2011-05-25 株式会社コーセー Oil makeup cosmetics
US7423015B1 (en) 2001-01-11 2008-09-09 Board Of Regents, The University Of Texas System Antihelminthic drugs as a treatment for hyperproliferative diseases
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
EP1379242B1 (en) * 2001-03-26 2012-08-15 Newsouth Innovations Pty Limited Method for treatment of cancer and compositions for use therein
CA2342470A1 (en) * 2001-03-30 2002-09-30 David Lawson Morris Method for treatment of cancer and benzimidazole compositions for use therein
CN101035530B (en) 2004-08-31 2013-07-03 新南部创新有限公司 VEGF inhibition

Also Published As

Publication number Publication date
CN101035530A (en) 2007-09-12
CA2576827A1 (en) 2006-03-09
PT1784181E (en) 2013-08-26
JP5022220B2 (en) 2012-09-12
PL1784181T3 (en) 2013-10-31
US20090105317A1 (en) 2009-04-23
US8912225B2 (en) 2014-12-16
HK1103651A1 (en) 2007-12-28
EP1784181A4 (en) 2009-06-03
EP1784181A1 (en) 2007-05-16
ES2425750T3 (en) 2013-10-17
EP1784181B1 (en) 2013-08-07
JP2008511549A (en) 2008-04-17
KR20070083538A (en) 2007-08-24
CN101035530B (en) 2013-07-03
WO2006024092A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
CY2019034I2 (en) 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES
NO2015023I2 (en) Sekukinumab
DE602005016654D1 (en) LTUNGSSYSTEM
DE602005004287D1 (en) PYRRAZOLOPYRIMIDINDERIVATE
ATE520680T1 (en) HIV-INHIBITING 5-HETEROCYCLYLPYRIMIDINES
ATE392425T1 (en) THIAZOLYL-DIHYDRO-INDAZOLES
ATE459633T1 (en) MACROLIDS
DE502005004843D1 (en) EINSPRITZVENTIL
DE602004004628D1 (en) Schlauchendsprühgerät
DE112005000809A5 (en) Wankstabilisierungseinrichtung
DE502005007739D1 (en) Kranballastierungssystem
DK1784181T3 (en) VEGF inhibition
NO20044110D0 (en) Stromskinne
DK1758870T3 (en) 4-phenyl-pyrimidine-2-carbonnitrilderivater
DE502004006772D1 (en) Effective tool-Barre
DE602005011231D1 (en) Kupplungsnachstellvorrichtung
ATE389633T1 (en) OMEGA-PHENYLOCTANAMIDE
DE112005000794T5 (en) Urethanspritzpistolenanordnung
DE602005026899D1 (en) Bildaufzeichungselement
AT500249A3 (en) SCHEIBENEGGE
DE602004011046D1 (en) Divinylfluorene
DE602004013423D1 (en) Kraftstoffverteilerkomponent
DE602004024247D1 (en) FILM-FINGERPRINTS
DE112005001019A5 (en) Kunststoffschraubverschlusskappe
AT7802U3 (en) PERFUME-ATOMIZERS